Table II.

Relative clinical and biochemical indices following a 12-week administration.

Group	ALT (U·l−1)	AST (U·l−1)	NEFA (mmol·l−1)	Fasting blood glucose (mg·dl−1)	Feeding blood glucose (mg·dl−1)	Insulin (pmol·l−1)	Leptin (ngm·l−1)
Control	31.5±0.26	105.3±1.41	0.17±0.02	63.2±4.7	95.6±10.1	142.6±36.5	20.04±1.2
Model	26.3±0.34a	95.4±0.97a	0.33±0.01a	73.5±3.6a	122.6±20.3a	188.7±42.2a	25.4±2.2a
A	23.7±0.65b	99.8±0.45b	0.23±0.05b	59.6±3.5b	92.6±16.8b	109.6±33.1b	19.6±2.5b
B	25.2±0.42	92.4±0.87	0.26±0.03	60.1±4.5b	95.8±17.6b	121.4±35.6b	22.3±0.8b
C	24.1±0.24b	99.3±0.64b	0.24±0.01b	64.5±1.2b	101.3±15.4	133.4±45.6b	20.4±1.5b
D	22.8±0.76b	91.5±0.75	0.24±0.05b	63.3±6.0b	97.8±11.9b	136.8±26.1b	21.8±3.3b

^aP<0.05 vs the control group

^bP<0.05 vs the model group. A-D, flavonoid A-D groups. ALT, alanine transaminase; AST, aspartate transaminase; NEFA, non-esterified fatty acids.